Comparison of Cd64 Levels Performed by the Facs and Accellix Systems

Sprung, CL; Morales, RC; Kasdan, Harvey L.; Reiter, A; Keren, S.; Meissonnier, Julien

doi:10.1186/2197-425x-3-s1-a1012

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…82 have used similar technology to show that measurement of CD64 (Accellix-CD64), the neutrophil activation marker, correlates well with standard flow cytometry 82 and that it is able to differentiate infection from non-infectious inflammation in a timely manner. 83…”

Section: Moving Toward Point-of-care Testingmentioning

confidence: 99%

“…Sprung et al 82 have used similar technology to show that measurement of CD64 (Accellix-CD64), the neutrophil activation marker, correlates well with standard flow cytometry 82 and that it is able to differentiate infection from non-infectious inflammation in a timely manner. 83 Further development of this type of automated technology is likely to lead to improved immune biomarker assays, which could allow a stratified medicine approach to immunomodulation in sepsis.…”

Section: Moving Toward Point-of-care Testingmentioning

confidence: 99%

See 1 more Smart Citation

Immune therapy in sepsis: Are we ready to try again?

Davies

O’Dea

Gordon

2018

Journal of the Intensive Care Society

View full text Add to dashboard Cite

Immune therapy to ease the burden of sepsis has thus far failed to consistently improve patient outcomes. Advances in cancer immune therapy and awareness that prolonged immune-suppression in sepsis can leave patients vulnerable to secondary infection and death have driven resurgence in the field of sepsis immune-therapy investigation. As we develop and evaluate these novel therapies, we must learn from past experiences where single-mediator targeted immune therapies were blindly delivered to heterogeneous patient cohorts with complex and evolving immune responses. Advances in genomics, proteomics, metabolomics, and point-of-care technology, coupled with a better understanding of sepsis pathogenesis, have meant that personalised immune-therapy is on the horizon. Here, we review the complex immune pathogenesis in sepsis and the contemporary immune therapies that are being investigated to manipulate this response. An outline of the immune biomarkers that may be used to support this approach is also provided.

show abstract

Section: Moving Toward Point-of-care Testingmentioning

confidence: 99%

Section: Moving Toward Point-of-care Testingmentioning

confidence: 99%

Immune therapy in sepsis: Are we ready to try again?

Davies

O’Dea

Gordon

2018

Journal of the Intensive Care Society

View full text Add to dashboard Cite

show abstract

“…Sample preparation and reading are performed in a dedicated disposable cartridge. Its first application was the measurement of neutrophil CD64 overexpression for diagnosis of bacterial infection [ 6 ]. The objective of the present study was to assess the analytical mHLA-DR measurement performance of Accellix cytometer.…”

Section: Introductionmentioning

confidence: 99%

Automated bedside flow cytometer for mHLA-DR expression measurement: a comparison study with reference protocol

Zouiouich

Gossez

Venet

et al. 2017

ICMx

View full text Add to dashboard Cite

BackgroundIn various ICU conditions, measurement of diminished expression of human leukocyte antigen-DR on circulating monocytes (mHLA-DR) by flow cytometry appears to be a reliable marker of acquired immunosuppression. Low mHLA-DR is associated with an increased risk of nosocomial infections and mortality. Nevertheless, its use remains somewhat limited and has not been adopted in common medical practice. The main drawback of mHLA-DR measurement is likely related to the use of flow cytometry that is not accessible everywhere on a 24/7 basis. Recently, the Accellix system, a fully automated table top cytometer, was developed for use at bedside or emergency labs.MethodsThe objective was to assess the performance of the Accellix (beta site evaluation including repeatability and method comparison with reference protocol) for the measurement of mHLA-DR expression.ResultsAccellix repeatability at low and high expression levels of mHLA-DR was < 10% (i.e., within the range of acceptability for clinical flow cytometry). In comparison study including 139 blood samples (67 septic shock patients and 17 healthy volunteers), Pearson’s correlation parameters (r 2) ranged from 0.71 to 0.97 (p < 0.001). Intra-class correlation coefficient was 0.92.ConclusionsThis fully automated table top cytometer appears to be a suitable tool for ICU patient monitoring and on-going clinical trials as there is no sample preparation and no need for specific skills in flow cytometry. Upon validation in a larger cohort study to reinforce reliability, Accellix could represent a major step to make flow cytometry accessible to clinicians by placing the instrument inside intensive care units or emergency laboratories.Electronic supplementary materialThe online version of this article (10.1186/s40635-017-0156-z) contains supplementary material, which is available to authorized users.

show abstract

Advances in the understanding and treatment of sepsis-induced immunosuppression

2017

View full text Add to dashboard Cite

Sepsis is defined as a life-threatening organ dysfunction that is caused by a dysregulated host response to infection. Sepsis can induce acute kidney injury and multiple organ failures and represents the most common cause of death in the intensive care unit. Sepsis initiates a complex immune response that varies over time, with the concomitant occurrence of both pro-inflammatory and anti-inflammatory mechanisms. As a result, most patients with sepsis rapidly display signs of profound immunosuppression, which is associated with deleterious consequences. Scientific advances have highlighted the role of metabolic failure, epigenetic reprogramming, myeloid-derived suppressor cells, immature suppressive neutrophils and immune alterations in primary lymphoid organs (the thymus and bone marrow) in sepsis. An improved understanding of the mechanisms underlying this immunosuppression as well as of the similarities between sepsis-induced immunosuppression and immune defects in cancer or immunosenescence has led to novel therapeutic strategies aimed at stimulating immune function in patients with sepsis. Trials assessing the therapeutic benefit of IL-7, granulocyte-macrophage colony-stimulating factor (GM-CSF) and antibodies against programmed cell death protein 1 (PD1) and programmed cell death 1 ligand 1 (PDL1) for the treatment of sepsis are in progress. The reappraisal of sepsis pathophysiology has also resulted in a novel approach to the design of clinical trials evaluating sepsis treatments, based on an evaluation of the immune status and biomarker-based stratification of patients.

show abstract

Comparison of Cd64 Levels Performed by the Facs and Accellix Systems

Cited by 4 publications

References 0 publications

Immune therapy in sepsis: Are we ready to try again?

Immune therapy in sepsis: Are we ready to try again?

Automated bedside flow cytometer for mHLA-DR expression measurement: a comparison study with reference protocol

Advances in the understanding and treatment of sepsis-induced immunosuppression

Contact Info

Product

Resources

About